FDA Licenses First At-Home Administered Influenza Vaccine
The U.S. Food and Drug Administration (FDA) has licensed the first of its kind live attenuated nasal spray influenza vaccine that can be administered at home. Adults up to the age 49 will be eligible to self-administer the FluMist Home vaccine or give it to their children two to 17 years old as long as […]
“Breakthrough Cases” of COVID-19 Emerging Among Fully Vaccinated Americans
The U.S. Centers for Disease Control and Prevention (CDC) recommends getting a COVID-19 vaccine, stating that, “COVID-19 vaccines are effective at protecting you from getting sick. Based on what we know about COVID-19 vaccines, people who have been fully vaccinated can start to do some things that they had stopped doing because of the pandemic.”1 […]
ACIP Updates Influenza Vaccine Guidelines for Seniors
The Advisory Committee on Immunization Practices (ACIP) for the U.S. Centers for Disease Control and Prevention (CDC) has issued new updates for influenza vaccines for 2020–2021 “flu season,” primarily for Fluzone and Fluad vaccines. In November 2019, U.S. Food and Drug Administration (FDA) licensed inactivated injectable Fluzone High-Dose Quadrivalent (HD-IIV4) for use in persons aged […]
Flu Vaccination Associated With Increased Viral Shedding
Opinion | When your body is infected with a disease-causing virus such as influenza, the virus is “shed” into the environment, via your saliva and other bodily fluids and skin lesions. If someone comes in contact with that shed virus, it’s possible that they, too, will become infected with the virus. There’s still a lot of […]
Intranasal COVID-19 Vaccine May Be More Effective Than Injected Vaccines
There are more than 150 experimental COVID-19 vaccines under development around the world, all of which are being designed for intramuscular injection.1 Some researchers are investigating whether the conventional intramuscular injection route is less effective when using vaccines to prevent microbial infections that invade the respiratory airway like SARS-CoV-2.2 Avery August, PhD, an immunologist at […]
